# Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

> **NCT00257673** · PHASE2 · COMPLETED · sponsor: **Memory Pharmaceuticals** · enrollment: 183 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** MEM 1003
- **DRUG:** MEM 1003
- **DRUG:** Placebo for MEM 1003

## Key facts

- **NCT ID:** NCT00257673
- **Lead sponsor:** Memory Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2008-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00257673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00257673, "Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00257673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*